Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838716 · ClinicalTrials.gov registry record · Phase 3
Vitamin D for Prostate Endocrine Therapy
A Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05838716 is a Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8 that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 240 participants, roughly in line with the 241-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT05838716, a Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- DRUG Placebo Administration
- PROCEDURE Dual X-ray Absorptiometry
- DIETARY_SUPPLEMENT D Vitamin
Study Locations (20)
Illinois
- Carle at The Riverfront - Danville
- Cancer Care Specialists of Illinois - Decatur - Decatur
- Carle Physician Group-Effingham - Effingham
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Cancer Care Center of O'Fallon - O'Fallon
- Carle Cancer Center - Urbana
Minnesota
- Mercy Hospital - Coon Rapids
- Minnesota Oncology Hematology PA-Maplewood - Maplewood
- Saint John's Hospital - Healtheast - Maplewood
- Park Nicollet Clinic - Saint Louis Park - Saint Louis Park
- Regions Hospital - Saint Paul
Kansas
- University of Kansas Cancer Center - Kansas City
- University of Kansas Cancer Center-Overland Park - Overland Park
- University of Kansas Health System Saint Francis Campus - Topeka
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Louisiana
- Louisiana State University Health Science Center - New Orleans
- University Medical Center New Orleans - New Orleans
- Ochsner Medical Center Jefferson - New Orleans
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2029-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05838716
The ClinicalTrials.gov registry entry for NCT05838716 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 241-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage III Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05838716 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Minnesota, Kansas.
Frequently Asked Questions
What is clinical trial NCT05838716 about?
NCT05838716 is a clinical study titled "Vitamin D for Prostate Endocrine Therapy". This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps th...
What is the current status of trial NCT05838716?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2023-12-14. Estimated completion is 2029-04-29.
What conditions does trial NCT05838716 study?
This clinical trial studies the following conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT05838716?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Placebo Administration (DRUG), Dual X-ray Absorptiometry (PROCEDURE), D Vitamin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05838716?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838716 being conducted?
This trial has 20 study locations across Delaware, Illinois, Kansas, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
RECRUITING · Phase 3
-
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
RECRUITING · Phase 3
-
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Stage III Prostate Cancer AJCC v8
All registered trials for this condition
Stage IVA Prostate Cancer AJCC v8
All registered trials for this condition
Delaware
All trials with a study site in Delaware
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.